Research programme: nanoparticle antibacterials - Techulon

Drug Profile

Research programme: nanoparticle antibacterials - Techulon

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Techulon
  • Class
  • Mechanism of Action DNA synthesis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections(Treatment-resistant) in USA (Parenteral)
  • 13 May 2013 Techulon receives phase II grant from Defense Advanced Research Projects Agency for nanoparticle antibacterial development in bacterial infections (treatment resistant)
  • 09 May 2013 Early research in Bacterial infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top